公司资料
Catalent 股价、新闻与催化剂
- 股票代码:
- CTLT
- 交易所:
- NYSE
- 行业:
- Biopharma
- 所在地:
- United States
股价为何变动
Current closing-price context is not available for CTLT.
公司概览
业务概览
Catalent was a pharmaceutical development and delivery company that supported drug formulation, manufacturing, and packaging before being acquired and taken private. It played a major role in outsourced pharma and biotech operations.
所在地与行业分类
Catalent was headquartered in the United States and traded on NYSE before the acquisition. It sat in contract development and manufacturing rather than therapeutics.
商业模式特征
The company generated revenue from manufacturing, development, fill-finish, and delivery services for pharma customers. Investors historically watched outsourcing demand, production utilization, and margin recovery.
生物医药行业定位
Catalent was a major infrastructure name for biotech and pharma, especially in manufacturing and delivery services. Because it has been acquired, it now belongs to historical sector infrastructure rather than the live public-company universe.
未来催化剂
- Catalent’s near-term catalysts are still transaction-related, with integration, divestiture, and site-rationalization milestones doing most of the work. That matters because demand only becomes valuable if the company can actually deliver at scale. Any improvement in supply or capacity can change how investors think about the next leg of the revenue curve.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。